Fagron has received regulatory clearance to acquire Vepakum, a Brazilian company, and has completed its acquisition of Magilab, based in Hungary. These transactions expand Fagron’s presence in both South America and Europe.
The acquisitions align with Fagron’s strategy to grow its global footprint in pharmaceutical compounding and related services.
**Why this matters**
The approval for the Vepakum acquisition allows Fagron to strengthen its operations in the Brazilian market, enhancing its capacity to serve local customers. Completing the Magilab acquisition further supports Fagron’s expansion in Central Europe, contributing to its long-term growth objectives.
Source: NewsData